Literature DB >> 31413125

CRISPR/Cas9-Mediated Knockout and In Situ Inversion of the ORF57 Gene from All Copies of the Kaposi's Sarcoma-Associated Herpesvirus Genome in BCBL-1 Cells.

Andrew BeltCappellino1, Vladimir Majerciak2, Alexei Lobanov3, Justin Lack3,4, Maggie Cam3, Zhi-Ming Zheng2.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV)-transformed primary effusion lymphoma cell lines contain ∼70 to 150 copies of episomal KSHV genomes per cell and have been widely used for studying the mechanisms of KSHV latency and lytic reactivation. Here, we report the first complete knockout (KO) of viral ORF57 gene from all ∼100 copies of KSHV genome per cell in BCBL-1 cells. This was achieved by a modified CRISPR/Cas9 technology to simultaneously express two guide RNAs (gRNAs) and Cas9 from a single expression vector in transfected cells in combination with multiple rounds of cell selection and single-cell cloning. CRISPR/Cas9-mediated genome engineering induces the targeted gene deletion and inversion in situ We found the inverted ORF57 gene in the targeted site in the KSHV genome in one of two characterized single cell clones. Knockout of ORF57 from the KSHV genome led to viral genome instability, thereby reducing viral genome copies and expression of viral lytic genes in BCBL-1-derived single-cell clones. The modified CRISPR/Cas9 technology was very efficient in knocking out the ORF57 gene in iSLK/Bac16 and HEK293/Bac36 cells, where each cell contains only a few copies of the KSHV genome. The ORF57 KO genome was stable in iSLK/Bac16 cells, and, upon lytic induction, was partially rescued by ectopic ORF57 to express viral lytic gene ORF59 and produce infectious virions. Together, the technology developed in this study has paved the way to express two separate gRNAs and the Cas9 enzyme simultaneously in the same cell and could be efficiently applied to any genetic alterations from various genomes, including those in extreme high copy numbers.IMPORTANCE This study provides the first evidence that CRISPR/Cas9 technology can be applied to knock out the ORF57 gene from all ∼100 copies of the KSHV genome in primary effusion lymphoma (PEL) cells by coexpressing two guide RNAs (gRNAs) and Cas9 from a single expression vector in combination with single-cell cloning. The gene knockout efficiency in this system was evaluated rapidly using a direct cell PCR screening. The current CRISPR/Cas9 technology also mediated ORF57 inversion in situ in the targeted site of the KSHV genome. The successful rescue of viral lytic gene expression and infectious virion production from the ORF57 knockout (KO) genome further reiterates the essential role of ORF57 in KSHV infection and multiplication. This modified technology should be useful for knocking out any viral genes from a genome to dissect functions of individual viral genes in the context of the virus genome and to understand their contributions to viral genetics and the virus life cycle. This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.

Entities:  

Keywords:  BCBL-1; CRISPR; Cas9; Kaposi's sarcoma-associated herpesvirus; ORF57; PEL cells; gene inversion; knockout

Mesh:

Substances:

Year:  2019        PMID: 31413125      PMCID: PMC6803266          DOI: 10.1128/JVI.00628-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  84 in total

1.  Viral FGARAT Homolog ORF75 of Rhesus Monkey Rhadinovirus Effects Proteasomal Degradation of the ND10 Components SP100 and PML.

Authors:  Alexander S Hahn; Anna K Großkopf; Doris Jungnickl; Brigitte Scholz; Armin Ensser
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

2.  Precise and Predictable CRISPR Chromosomal Rearrangements Reveal Principles of Cas9-Mediated Nucleotide Insertion.

Authors:  Jia Shou; Jinhuan Li; Yingbin Liu; Qiang Wu
Journal:  Mol Cell       Date:  2018-07-19       Impact factor: 17.970

3.  Gene structure and expression of Kaposi's sarcoma-associated herpesvirus ORF56, ORF57, ORF58, and ORF59.

Authors:  Vladimir Majerciak; Koji Yamanegi; Zhi-Ming Zheng
Journal:  J Virol       Date:  2006-10-04       Impact factor: 5.103

4.  Kaposi's sarcoma-associated herpesvirus lytic gene ORF57 is essential for infectious virion production.

Authors:  Zhao Han; Sankar Swaminathan
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  ORF57 overcomes the detrimental sequence bias of Kaposi's sarcoma-associated herpesvirus lytic genes.

Authors:  Carolin Vogt; Christian Hackmann; Alona Rabner; Lars Koste; Susann Santag; Semra Kati; Yael Mandel-Gutfreund; Thomas F Schulz; Jens Bohne
Journal:  J Virol       Date:  2015-02-18       Impact factor: 5.103

6.  Caspase-7 cleavage of Kaposi sarcoma-associated herpesvirus ORF57 confers a cellular function against viral lytic gene expression.

Authors:  Vladimir Majerciak; Michael Kruhlak; Pradeep K Dagur; J Philip McCoy; Zhi-Ming Zheng
Journal:  J Biol Chem       Date:  2010-02-16       Impact factor: 5.157

7.  Identification of the physiological gene targets of the essential lytic replicative Kaposi's sarcoma-associated herpesvirus ORF57 protein.

Authors:  Dinesh Verma; Da-Jiang Li; Brian Krueger; Rolf Renne; Sankar Swaminathan
Journal:  J Virol       Date:  2014-11-19       Impact factor: 5.103

8.  Multiple regions of Kaposi's sarcoma-associated herpesvirus ORF59 RNA are required for its expression mediated by viral ORF57 and cellular RBM15.

Authors:  Maria Julia Massimelli; Vladimir Majerciak; Jeong-Gu Kang; David J Liewehr; Seth M Steinberg; Zhi-Ming Zheng
Journal:  Viruses       Date:  2015-02-03       Impact factor: 5.048

9.  Generation of megabase-scale deletions, inversions and duplications involving the Contactin-6 gene in mice by CRISPR/Cas9 technology.

Authors:  Alexei N Korablev; Irina A Serova; Oleg L Serov
Journal:  BMC Genet       Date:  2017-12-28       Impact factor: 2.797

10.  SIRT1-mediated downregulation of p27Kip1 is essential for overcoming contact inhibition of Kaposi's sarcoma-associated herpesvirus transformed cells.

Authors:  Meilan He; Hongfeng Yuan; Brandon Tan; Rosemary Bai; Heon Seok Kim; Sangsu Bae; Lu Che; Jin-Soo Kim; Shou-Jiang Gao
Journal:  Oncotarget       Date:  2016-11-15
View more
  16 in total

1.  Protein-RNA Interactome Analysis Reveals Wide Association of Kaposi's Sarcoma-Associated Herpesvirus ORF57 with Host Noncoding RNAs and Polysomes.

Authors:  Beatriz Alvarado-Hernandez; Yanping Ma; Nishi R Sharma; Vladimir Majerciak; Alexei Lobanov; Maggie Cam; Jun Zhu; Zhi-Ming Zheng
Journal:  J Virol       Date:  2021-11-17       Impact factor: 6.549

Review 2.  Genome-editing approaches and applications: a brief review on CRISPR technology and its role in cancer.

Authors:  Narmadhaa Siva; Sonal Gupta; Ayam Gupta; Jayendra Nath Shukla; Babita Malik; Nidhi Shukla
Journal:  3 Biotech       Date:  2021-02-26       Impact factor: 2.406

3.  CRISPR Interference Efficiently Silences Latent and Lytic Viral Genes in Kaposi's Sarcoma-Associated Herpesvirus-Infected Cells.

Authors:  Kevin Brackett; Ameera Mungale; Mary Lopez-Isidro; Duncan A Proctor; Guillermo Najarro; Carolina Arias
Journal:  Viruses       Date:  2021-04-28       Impact factor: 5.048

4.  Reversible switching of primary cells between normal and malignant state by oncogenic virus KSHV and CRISPR/Cas9-mediated targeting of a major viral latent protein.

Authors:  Enguo Ju; Tingting Li; Suzane Ramos da Silva; Ashley Markazi; Shou-Jiang Gao
Journal:  J Med Virol       Date:  2021-05-03       Impact factor: 20.693

Review 5.  Designer nucleases to treat malignant cancers driven by viral oncogenes.

Authors:  Tristan A Scott; Kevin V Morris
Journal:  Virol J       Date:  2021-01-13       Impact factor: 4.099

6.  Targeting the Kaposi's sarcoma-associated herpesvirus genome with the CRISPR-Cas9 platform in latently infected cells.

Authors:  Coral Orel Haddad; Inna Kalt; Yehuda Shovman; Lei Xia; Yehuda Schlesinger; Ronit Sarid; Oren Parnas
Journal:  Virol J       Date:  2021-03-17       Impact factor: 4.099

7.  CRISPR/Cas9 ablating viral microRNA promotes lytic reactivation of Kaposi's sarcoma-associated herpesvirus.

Authors:  Zhipin Liang; Zhiqiang Qin; Adam I Riker; Yaguang Xi
Journal:  Biochem Biophys Res Commun       Date:  2020-10-19       Impact factor: 3.575

8.  Generation of A Triple Insert Live Avian Herpesvirus Vectored Vaccine Using CRISPR/Cas9-Based Gene Editing.

Authors:  Na Tang; Yaoyao Zhang; Yashar Sadigh; Katy Moffat; Zhiqiang Shen; Venugopal Nair; Yongxiu Yao
Journal:  Vaccines (Basel)       Date:  2020-02-21

9.  Quantitative Proteomics Analysis of Lytic KSHV Infection in Human Endothelial Cells Reveals Targets of Viral Immune Modulation.

Authors:  Ildar Gabaev; James C Williamson; Thomas W M Crozier; Thomas F Schulz; Paul J Lehner
Journal:  Cell Rep       Date:  2020-10-13       Impact factor: 9.423

Review 10.  CRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical Trials.

Authors:  Khalil Khalaf; Krzysztof Janowicz; Marta Dyszkiewicz-Konwińska; Greg Hutchings; Claudia Dompe; Lisa Moncrieff; Maurycy Jankowski; Marta Machnik; Urszula Oleksiewicz; Ievgeniia Kocherova; Jim Petitte; Paul Mozdziak; Jamil A Shibli; Dariusz Iżycki; Małgorzata Józkowiak; Hanna Piotrowska-Kempisty; Mariusz T Skowroński; Paweł Antosik; Bartosz Kempisty
Journal:  Genes (Basel)       Date:  2020-08-11       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.